ArticleScientific reports2026
Prognostic role of CDCA3 in lung adenocarcinoma with immune infiltration.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung cancer is a leading cause of cancer-related deaths, often resistant to conventional therapies like platinum-based chemotherapy. Identifying new biomarkers and therapeutic targets is essential for improving outcomes. In this study, we explored the role of CDCA3 in lung adenocarcinoma (LUAD) as a prognostic marker and its association with immune cell infiltration and immunotherapy. Using data from The Cancer Genome Atlas (TCGA), we evaluated CDCA3 expression and its prognostic significance through Kaplan-Meier survival analysis. Our results showed that CDCA3 was significantly upregulated in LUAD tumor tissues compared to normal tissues, with higher CDCA3 expression linked to poorer overall survival. Additionally, CDCA3 expression correlated with clinical features such as age, gender, cancer stage, and smoking status. Immune infiltration analysis revealed significant associations with CD4-activated memory T cells and macrophages. Single‑cell transcriptomics revealed that the proportions of CD8⁺ exhausted T cells, CD8⁺ cytotoxic T cells, M1 macrophages and M2 macrophages varied in association with CDCA3 expression levels in LUAD. CDCA3 expression also correlated with immune scores and immune checkpoint gene expression. Drug sensitivity analysis using the "oncoPredict" R package suggested that CDCA3 expression may influence chemotherapy responses. In vitro experiments in A549 cells showed that CDCA3 knockdown significantly reduced CDCA3 expression at both the mRNA and protein levels. While flow cytometry indicated increased apoptosis in CDCA3-knockdown cells, suggesting CDCA3's role in promoting LUAD cell proliferation and survival. These findings indicated that CDCA3 could serve as a valuable prognostic biomarker in LUAD, influencing prognosis, immune response, and drug sensitivity, potentially guiding therapeutic and immunotherapy decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.